BPC-157 vs TB-500:
what's the difference?

Short answer

BPC-157 is a 15-amino-acid peptide derived from a protein in gastric juice, studied mainly for localised tissue and gut repair. TB-500 is a synthetic fragment of thymosin beta-4 (TB-4), studied for cell migration and systemic tissue repair. They're distinct peptides with distinct mechanisms, both preclinical, and neither is an FDA-approved drug.

What each one is

BPC-157 (“Body Protection Compound”) is a synthetic pentadecapeptide — fifteen amino acids — derived from a protein found in gastric juice, and research focuses on localised tendon, muscle and gut-tissue models. TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein, and research focuses on cell migration and more systemic repair processes.

How they differ — and what's the same

The practical difference researchers describe is scope of action: BPC-157 is studied more for a specific injured area, TB-4/TB-500 for broader cell movement and recovery signalling. What they share matters more for you: both sit on preclinical evidence, both appear on the WADA prohibited list, and neither is FDA-approved. BPC Matrix combines both — with KPV and MGF — in one physician-access blend, which is a formulation decision a clinician oversees.

All research & answers BPC-157 TB-500 / TB-4 KPV MGF